MedTrace Logo

Treatment Responses of Early Syphilis to Ceftriaxone Plus Doxycycline

NCT05980871 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 109

Last updated 2026-02-25

Study results available
· View outcomes & findings →

Summary

In a prospective study investigating the prevalence of sexually transmitted infections (STIs) among at-risk people living with HIV (PLWH), the prevalence of Chlamydia trachomatis and Neisseria gonorrhoeae was 24.7% and 12.1%, respectively. Surprisingly, the study found high rates of C. trachomatis and/or N. gonorrhoeae co-infections in PLWH with recent hepatitis C virus (HCV) infection (50%), HBsAg positivity (44%), and early syphilis (36%). Considering the high rate of sexually transmitted co-infections, combination therapy of single-dose ceftriaxone plus 7-day doxycycline for early syphilis may provide convenience and benefit to treatment of N. gonorrhoeae and C. trachomatis co-infections at a single clinic encounter. In the present study, this study aim to compare the efficacy of ceftriaxone plus doxycycline versus benzathine penicillin G (BPG) plus doxycycline as the treatment for early syphilis among PLWH.

Conditions

  • Early Syphilis

Interventions

DRUG

Doxycycline

doxycycline (100 mg orally twice daily for 7 days)

DRUG

Ceftriaxone

Ceftriaxone (1g intramuscularly once)

DRUG

benzathine penicillin G

benzathine penicillin G (2.4 MU intramuscularly once)

Sponsors & Collaborators

  • National Taiwan University Hospital

    lead OTHER

Principal Investigators

  • Kuan-Yin Lin · National Taiwan University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-10
Primary Completion
2025-07-25
Completion
2025-07-25

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05980871 on ClinicalTrials.gov